SLNO vs. SNN, SOLV, PEN, STVN, GKOS, NARI, IRTC, TMDX, BLCO, and INSP
Should you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Smith & Nephew (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Bausch + Lomb (BLCO), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry.
Soleno Therapeutics vs.
Soleno Therapeutics (NASDAQ:SLNO) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
Smith & Nephew has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.
Soleno Therapeutics has a beta of -2.69, meaning that its stock price is 369% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.
Smith & Nephew's return on equity of 0.00% beat Soleno Therapeutics' return on equity.
Smith & Nephew received 126 more outperform votes than Soleno Therapeutics when rated by MarketBeat users. However, 72.75% of users gave Soleno Therapeutics an outperform vote while only 54.10% of users gave Smith & Nephew an outperform vote.
In the previous week, Smith & Nephew had 1 more articles in the media than Soleno Therapeutics. MarketBeat recorded 7 mentions for Smith & Nephew and 6 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 1.67 beat Smith & Nephew's score of 0.90 indicating that Soleno Therapeutics is being referred to more favorably in the media.
97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew shares are held by institutional investors. 12.3% of Soleno Therapeutics shares are held by insiders. Comparatively, 1.0% of Smith & Nephew shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Soleno Therapeutics presently has a consensus target price of $106.78, suggesting a potential upside of 33.81%. Smith & Nephew has a consensus target price of $28.00, suggesting a potential downside of 6.90%. Given Soleno Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Soleno Therapeutics is more favorable than Smith & Nephew.
Summary
Smith & Nephew beats Soleno Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Soleno Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soleno Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SLNO) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy SLNO Stock Free SLNO Stock Alerts